{
    "root": "2f9eead4-1b34-d484-e063-6294a90afd42",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ketorolac Tromethamine",
    "value": "20250305",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "KETOROLAC TROMETHAMINE",
            "code": "4EVE5946BQ"
        }
    ],
    "indications": "carefully consider potential benefits risks ketorolac tromethamine tablets treatment options deciding ketorolac tromethamine tablets . lowest effective dose shortest duration consistent individual patient treatment goals .",
    "contraindications": "carefully consider potential benefits risks ketorolac tromethamine tablets treatment options deciding ketorolac tromethamine tablets . lowest effective dose shortest duration consistent individual patient treatment goals . adults , combined duration intravenous intramuscular dosing ketorolac tromethamine ketorolac tromethamine tablets exceed 5 days . adults , ketorolac tromethamine tablets indicated continuation therapy intravenous intramuscular dosing ketorolac tromethamine . transition intravenous intramuscular dosing ketorolac tromethamine ( single- multiple-dose ) multiple-dose ketorolac tromethamine tablets : patients age 17 64 : 20 mg po followed 10 mg q4 hours 6 hours prn > 40 mg/day patients age \u2265 65 , renally impaired , and/or weight < 50 kg ( 110 lbs ) : 10 mg po followed 10 mg q4 hours 6 hours prn > 40 mg/day note : oral formulationshould notbe given initial dose minimum effective dosefor individual patient shorten dosing intervalof 4 hours 6 hours total duration treatment adult patients : combined duration intravenous intramuscular dosing ketorolac tromethamine ketorolac tromethamine tablets exceed 5 days . following table summarizes ketorolac tromethamine tablets dosing instructions terms age group : table 4 : summary dosing instructions patient population ketorolac tromethamine tablets ( following intravenous intramuscular dosing ketorolac tromethamine ) age < 17 years oral approved adult age 17 years 64 years 20 mg , 10 mg q4 hours 6 hours prn > 40 mg/day adult age \u2265 65 years , renally impaired , and/or weight < 50 kg 10 mg , 10 mg q4 hours 6 hours prn > 40 mg/day",
    "warningsAndPrecautions": "ketorolac tromethamine tablets , usp 10 mg round , white , convex , unscored , film\u2011coated tablets , debossed \u201c kt \u201d one side plain side , available bottles 100 tablets ( ndc 69452-275-20 ) . storage store 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . protect light excessive humidity . keep medications reach children . distributed : bionpharma inc. princeton , nj 08540 made india rev . 11/2024 fda-07 948026854",
    "adverseReactions": "( also boxed warning ) . ketorolac tromethamine contraindicated patients previously demonstrated hypersensitivity ketorolac tromethamine . ketorolac tromethamine contraindicated patients active peptic ulcer disease , patients recent gastrointestinal bleeding perforation patients history peptic ulcer disease gastrointestinal bleeding . ketorolac tromethamine given patients experienced asthma , urticaria , allergic-type taking aspirin nsaids . severe , rarely fatal , anaphylactic-like nsaids reported patients ( , anaphylactoid , , preexisting asthma ) . ketorolac tromethamine contraindicated prophylactic analgesic major surgery . ketorolac tromethamine contraindicated setting coronary artery bypass graft ( cabg ) surgery ( ) . ketorolac tromethamine contraindicated patients advanced renal impairment patients risk renal failure due volume depletion ( correction volume depletion ) . ketorolac tromethamine contraindicated labor delivery , prostaglandin synthesis inhibitory effect , may adversely affect fetal circulation inhibit uterine contractions , thus increasing risk uterine hemorrhage . ketorolac tromethamine inhibits platelet function , therefore , contraindicated patients suspected confirmed cerebrovascular bleeding , hemorrhagic diathesis , incomplete hemostasis high risk bleeding ( ) . ketorolac tromethamine contraindicated patients currently receiving aspirin nsaids cumulative risks inducing serious nsaid-related events . concomitant ketorolac tromethamine probenecid contraindicated . concomitant ketorolac tromethamine pentoxifylline contraindicated .",
    "indications_original": "Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.",
    "contraindications_original": "Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. In adults, the combined duration of use of\u00a0intravenous or intramuscular dosing of ketorolac tromethamine and ketorolac tromethamine tablets is not to exceed 5 days. In adults, the use of ketorolac tromethamine tablets is only indicated as continuation therapy to\u00a0intravenous or intramuscular dosing of ketorolac tromethamine.\n                  \n                  \n                     Transition from\u00a0intravenous or intramuscular dosing of ketorolac tromethamine (single- or multiple-dose) to multiple-dose ketorolac tromethamine tablets:\n                  \n                  Patients age 17 to 64: 20 mg PO once followed by 10 mg q4 hours to 6 hours prn\n \n  not > 40 mg/day\n                  \n                  Patients age \u2265 65, renally impaired, and/or weight < 50 kg (110 lbs): 10 mg PO once followed by 10 mg q4 hours to 6 hours prn\n \n  not > 40 mg/day\n                  \n                  \n                     Note:\n                  \n                  \n                     Oral formulationshould\n \n  notbe given\n \n  as an initial dose\n                  \n                  \n                     Use minimum effective dosefor the individual patient\n\n \n                  Do\n \n  not shorten dosing intervalof 4\u00a0hours to 6 hours\n\n \n                  \n                     Total duration of treatment in adult patients:the combined duration of use of\u00a0intravenous or intramuscular dosing of ketorolac tromethamine and ketorolac tromethamine tablets is not to exceed 5 days.\n\n \n                  The following table summarizes ketorolac tromethamine tablets dosing instructions in terms of age group:\n                  \n                     Table 4: Summary of Dosing Instructions\n                     \n                     \n                     \n                        \n                           \n                              \n                                 Patient Population\n                              \n                           \n                           \n                              \n                                 Ketorolac Tromethamine Tablets (Following\u00a0Intravenous or Intramuscular dosing of ketorolac tromethamine)\n                              \n                           \n                        \n                        \n                           \n                              Age < 17 years\n                           \n                           \n                              Oral not approved\n                           \n                        \n                        \n                           \n                              Adult Age 17\u00a0years to 64 years\n                           \n                           \n                              20 mg once, then 10 mg q4 hours to 6 hours prn not > 40 mg/day\n                           \n                        \n                        \n                           \n                              Adult Age \u2265 65 years, renally impaired, and/or weight < 50 kg\n                           \n                           \n                              10 mg once, then 10 mg q4 hours to 6 hours prn not > 40 mg/day",
    "warningsAndPrecautions_original": "Ketorolac tromethamine tablets, USP 10 mg are round, white, convex, unscored, film\u2011coated tablets, debossed \u201c \n  KT\u201d on one side and plain on the other side, available in bottles of 100 tablets (NDC 69452-275-20).\n \n                  \n                  \n                     Storage\n                  \n                  Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  PROTECT FROM LIGHT AND EXCESSIVE HUMIDITY.\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  \n                  Distributed by:\n  \n                     Bionpharma Inc.\n                     \nPrinceton, NJ 08540\n \n                  \n                  \n                     MADE IN INDIA\n                  \n                  Rev. 11/2024\n                  FDA-07\n                  948026854",
    "adverseReactions_original": "(See also\u00a0\n \n  \n                        Boxed WARNING\n                     ).\n\n \n                  Ketorolac tromethamine\u00a0is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine.\n                  Ketorolac tromethamine is contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding.\n                  Ketorolac tromethamine should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see\n \n  \n                        \n                           WARNINGS\n                        \n                     \n                     ,\u00a0\n                     \n                        Anaphylactoid Reactions\n                     , and\n \n  \n                        \n                           PRECAUTIONS\n                        \n                     \n                     ,\u00a0\n                     \n                        Preexisting Asthma\n                     ).\n\n \n                  Ketorolac tromethamine\u00a0is contraindicated as prophylactic analgesic before any major surgery.\n                  Ketorolac tromethamine is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see\n \n  \n                        WARNINGS\n                     ).\n\n \n                  Ketorolac tromethamine is contraindicated in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion (see\n \n  \n                        WARNINGS\n                     for correction of volume depletion).\n\n \n                  Ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage.\n                  Ketorolac tromethamine inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see\n \n  \n                        WARNINGS\n                     and\n \n  \n                        PRECAUTIONS\n                     ).\n\n \n                  Ketorolac tromethamine\u00a0is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events.\n                  The concomitant use of ketorolac tromethamine and probenecid is contraindicated.\n                  The concomitant use of ketorolac tromethamine and pentoxifylline is contraindicated."
}